The Manufacturers Life Insurance Company Has $172.66 Million Position in Hologic, Inc. $HOLX

Key Points

• The Manufacturers Life Insurance Company increased its stake in Hologic, Inc. by 17.1%, acquiring an additional 408,535 shares, bringing its total holdings to approximately 2.8 million shares valued at $172.7 million.
• Analysts have set a consensus price target of $78.00 for Hologic, with seven ratings of Buy, eight of Hold, and one Strong Buy, reflecting positive sentiment among analysts.
• Hologic reported earnings of $1.08 per share for the last quarter, exceeding analyst estimates, with a revenue increase of 1.2% from the previous year, totaling $1.02 billion.

The Manufacturers Life Insurance Company grew its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 17.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,795,137 shares of the medical equipment provider's stock after acquiring an additional 408,535 shares during the quarter. The Manufacturers Life Insurance Company owned 1.25% of Hologic worth $172,656,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Farther Finance Advisors LLC grew its holdings in shares of Hologic by 22.3% during the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after buying an additional 335 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Hologic by 116.6% during the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock worth $594,000 after buying an additional 5,172 shares in the last quarter. Brevan Howard Capital Management LP grew its holdings in shares of Hologic by 85.5% during the fourth quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock worth $1,401,000 after buying an additional 8,960 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Hologic by 1.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock worth $1,980,000 after buying an additional 528 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its holdings in shares of Hologic by 4.5% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 17,945 shares of the medical equipment provider's stock worth $1,108,000 after buying an additional 767 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on HOLX. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. UBS Group raised their price target on Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, July 31st. Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and raised their price target for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Finally, Morgan Stanley raised their price target on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $78.00.

Hologic Stock Performance

Shares of HOLX traded down $0.27 during mid-day trading on Thursday, reaching $65.97. The company's stock had a trading volume of 347,380 shares, compared to its average volume of 2,704,196. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The stock has a market cap of $14.67 billion, a P/E ratio of 27.38, a PEG ratio of 2.44 and a beta of 0.57. The business has a 50-day simple moving average of $66.28 and a two-hundred day simple moving average of $62.57. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same period last year, the firm posted $1.06 earnings per share. The business's revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.